Thirty-day mortality rates after immunotherapy initiation.

Area of Science:

• Oncology
• Immunotherapy research
• Clinical outcomes

Background:

• Immunotherapy has revolutionized cancer treatment.
• Understanding early mortality risks associated with immunotherapy is crucial for patient safety.
• Identifying factors contributing to early death post-immunotherapy is an unmet clinical need.

Purpose of the Study:

• To investigate the causes of death within 30 days following the initial dose of immunotherapy.
• To identify patient subgroups at higher risk for fatal adverse events.
• To inform clinical decision-making regarding immunotherapy initiation and management.

Main Methods:

• Retrospective analysis of 1432 patients receiving immunotherapy across six tertiary referral hospitals.
• Data collection focused on mortality within 30 days of the first immunotherapy dose.
• Categorization of causes of death and patient treatment lines.

Main Results:

• A total of 34 patients (2%) died within 30 days of their first immunotherapy dose.
• All patients who died had received palliative therapy.
• The majority of patients (88%) received immunotherapy as second- or subsequent-line treatment.
• Disease progression and thromboembolic events were the most frequent causes of death.

Conclusions:

• Early mortality after immunotherapy is a rare but significant event.
• Patients receiving palliative care or later-line immunotherapy may be at increased risk.
• Further research is needed to define patient populations susceptible to fatal immunotherapy side effects.